Beijing Luzhu Biotechnology Co., Ltd. (Luzhu Biotech-B) filed its Monthly Return for the period ended 31 March 2026, confirming a stable capital structure with no share movements during the month.

The company’s issued share capital stood unchanged at 202.45 million ordinary H shares with a par value of RMB 1.00 each. Of these, 3.54 million shares are held as treasury stock, leaving 198.91 million shares in public circulation.

Luzhu Biotech-B affirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 25%, based on publicly available information.

No new share options, warrants, convertible securities, or other equity instruments were issued, exercised, or cancelled during March. There were also no movements involving Hong Kong Depositary Receipts.

The filing was authorised by Joint Company Secretary Liu Siyu, who confirmed that all regulatory obligations and listing rule requirements have been met.